Innoviva, Inc.
INVANasdaq
$21.71
↓ -2.3%Jul 17 close · end-of-day
Price
1Y↑ +7.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8B
Enterprise Value
$1.5B
P/E
3.5
P/S
4.4
P/B
1.4
EV/EBITDA
—
PEG
0.3
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$420.7M
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
73.7%
Operating Margin
38.1%
Net Margin
—
ROE
—
ROIC
13.5%
Debt / Equity
0.2
Net Cash
$345.0M
Return 1Y
+9.2%
Company profile
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
- CEO
- Pavel Raifeld
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- California
- Website
- inva.com
Management & directors
- Basso StephenChief Financial Officer
- Raifeld PavelChief Executive Officer
- Zhen MarianneChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
INVA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$98.0M↑ +10.6%
Diluted EPS$2.22↓ -400.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $336.8M | $391.9M | $331.3M | $310.5M | $358.7M | $411.3M |
| Gross profit | — | — | — | $246.0M | $296.2M | $307.7M |
| Operating income | $321.1M | $375.1M | — | $113.9M | $166.9M | $163.7M |
| Net income | — | — | — | — | — | — |
| Diluted EPS | $2.02 | $2.87 | $2.37 | $2.20 | $0.36 | $3.30 |
| Operating cash flow | $313.1M | $363.8M | $201.7M | $141.1M | $188.7M | $196.9M |
| Free cash flow | $313.1M | $363.8M | $201.7M | $140.7M | $188.4M | $195.8M |
| Gross margin | — | — | — | 79.2% | 82.6% | 74.8% |
| Operating margin | 95.3% | 95.7% | — | 36.7% | 46.5% | 39.8% |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $99.9M | $89.5M | $91.8M | $88.6M | $100.3M | $107.8M | $114.6M | $98.0M |
| Gross profit | $85.0M | $73.0M | $78.1M | $73.3M | $83.1M | $75.5M | $75.7M | $75.8M |
| Operating income | $54.7M | $43.2M | $43.1M | $41.4M | $48.8M | $34.6M | $39.0M | $38.2M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$0.55 | $0.02 | $0.43 | -$0.74 | $0.77 | $1.08 | $2.19 | $2.22 |
| Operating cash flow | $43.7M | $48.7M | $59.2M | $48.6M | $44.1M | $49.7M | $54.5M | $35.3M |
| Free cash flow | $43.7M | $48.4M | $59.2M | $48.6M | — | — | — | $34.8M |
| Gross margin | 85.1% | 81.6% | 85.1% | 82.7% | 82.9% | 70.1% | 66.0% | 77.4% |
| Operating margin | 54.7% | 48.3% | 47.0% | 46.7% | 48.6% | 32.1% | 34.0% | 38.9% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 1, 2026
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Raifeld Pavel· Chief Executive Officer | Tax withholding | 1,130 | $22.24 | $25,131.20 | filing |
| 2026-05-20 | Zhen Marianne· Chief Accounting Officer | Tax withholding | 1,127 | $22.24 | $25,064.48 | filing |
| 2026-05-20 | Basso Stephen· Chief Financial Officer | Tax withholding | 559 | $22.24 | $12,432.16 | filing |
| 2026-05-18 | Linden Josephine | Award | 9,461 | $0.00 | $0.00 | filing |
| 2026-05-18 | Linden Josephine | Award | 5,733 | $0.00 | $0.00 | filing |
| 2026-05-15 | Basso Stephen· Chief Financial Officer | Award | 1,123 | $0.00 | $0.00 | filing |
| 2026-05-15 | Raifeld Pavel· Chief Executive Officer | Award | 1,123 | $0.00 | $0.00 | filing |
| 2026-05-04 | Small Derek A | Award | 9,786 | $0.00 | $0.00 | filing |
| 2026-05-04 | Raifeld Pavel· Chief Executive Officer | Award | 126,646 | $0.00 | $0.00 | filing |
| 2026-05-04 | DiPaolo Mark | Award | 9,786 | $0.00 | $0.00 | filing |
| 2026-05-04 | Zhen Marianne· Chief Accounting Officer | Award | 12,766 | $0.00 | $0.00 | filing |
| 2026-05-04 | Schlesinger Sarah J. | Award | 9,786 | $0.00 | $0.00 | filing |
| 2026-05-04 | Basso Stephen· Chief Financial Officer | Award | 37,994 | $0.00 | $0.00 | filing |
| 2026-05-04 | Haimovitz Jules | Award | 9,786 | $0.00 | $0.00 | filing |
| 2026-02-20 | Raifeld Pavel· Chief Executive Officer | Tax withholding | 2,986 | $23.39 | $69,842.54 | filing |
| 2026-02-20 | Zhen Marianne· Chief Accounting Officer | Tax withholding | 2,460 | $23.39 | $57,539.40 | filing |
| 2026-02-20 | Basso Stephen· Chief Financial Officer | Tax withholding | 1,244 | $23.39 | $29,097.16 | filing |
| 2025-11-20 | Zhen Marianne· Chief Accounting Officer | Tax withholding | 992 | $21.16 | $20,990.72 | filing |
| 2025-11-20 | Basso Stephen· Chief Financial Officer | Tax withholding | 237 | $21.16 | $5,014.92 | filing |
| 2025-11-15 | Basso Stephen· Chief Financial Officer | Award | 604 | $0.00 | $0.00 | filing |
| 2025-11-03 | Raifeld Pavel | Award | 110,436 | $18.11 | $2.0M | filing |
| 2025-11-03 | Basso Stephen· Chief Financial Officer | Award | 27,609 | $18.11 | $499,998.99 | filing |
| 2025-08-20 | Zhen Marianne· Chief Accounting Officer | Tax withholding | 991 | $19.95 | $19,770.45 | filing |
| 2025-08-20 | Basso Stephen· Chief Financial Officer | Tax withholding | 237 | $19.95 | $4,728.15 | filing |
Latest 24 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.